Introduction
The Notch-signaling pathway plays an integral role in cell fate decisions in all organisms, mutations in the Notch receptor, or its ligands, resulting in developmental abnormalities and embryonic lethality (1) . Signaling through the cell surface receptor, Notch is activated by ligation to DSL (from: Delta, Serrate, and Lag proteins). In vertebrates there are four identified Notch the Notch ligand, Jagged-1, can induce peripheral tolerance to the house dust mite antigen Der p 1 (17) . Second, the Notch ligand Dl1 can inhibit the differentiation of monocytes into macrophages, but allows their differentiation into DCs (18) . Finally, in elegant studies involving conditional inactivation of the Notch pathway transcription factor, RBP-j, Tanigaki et al. (19) demonstrated that Notch signaling regulates the lineage commitment of mature peripheral B cells. As yet, however, there are no data addressing the activities of ligands of the Delta-like family on T cells nor the effects of Notch signaling on CD8 + cells. The aim of the studies reported here was to investigate the effects and mechanisms of action of Delta-mediated ligation of Notch on peripheral T cell-dependent immunity to transplantation antigens.
Methods

Production and characterization of Notch ligand transfectants.
L cells express endogenous MHC class I antigens of the H-2 k haplotype, but no endogenous MHC class II antigens. K b and A b (20) are L cells transfected with MHC class I (h-2K b ) or MHC class II (h-2A b ), respectively, of the H-2 b haplotype (kindly provided by K. Wood, University of Oxford, Oxford, United Kingdom). Mouse Dl1 cDNA was subcloned into the mammalian expression vector, pIRES2/enhanced GFP (EGFP) (BD Biosciences Clontech UK, Cowley, United Kingdom) for transfection into L cells using Effectene (Qiagen Ltd., Crawley, United Kingdom). Stable transfectants were selected in G418 (Life Technologies Ltd., Paisley, United Kingdom) and twice sorted using flow cytometry to produce a population of EGFP-expressing cells named K b /Dl1 and A b /Dl1. Control K b and A b transfected with empty pIRES/EGFP were similarly selected and shown to behave in the same way as the K b and A b cells in popliteal lymph node (PLN) assays.
Ab's. Biotinylated AF6-88 (anti-H-2K b ) and 1D9 (anti-H-2A b ) were provided by A. Livingstone (University of Rochester Medical Center, Rochester, New York, USA). Anti-CD3 (FITC conjugated), streptavidin-phycoerythrin, and annexin V staining kits were from PharMingen (Cowley, United Kingdom). Depleting CD8 (YTS169) and CD4 (YTS191) Ab's were a kind gift of S. Cobbold (University of Oxford, Oxford, United Kingdom) (21) . Rat Ig was from Sigma-Aldrich Co. Ltd. (Gillingham, United Kingdom).
Flow cytometry. Viable cells (10 5 ) were aliquoted into wells of a 96-well plate (Bibby Sterilin Ltd., Stone, United Kingdom) and incubated with titrated amounts of primary Ab's in 50 µl PBS/FCS. After washing, cells were resuspended with secondary Ab. Stained cells were analyzed using a FACscan II flow cytometer with Cellquest software (Becton-Dickinson UK Ltd., Oxford, United Kingdom).
Quantitative RT-PCR. Total RNA was extracted using StrataPrep (Stratagene Europe, Amsterdam, The Netherlands) or Qiagen RNeasy kits (Qiagen Ltd.). Total RNA (400-500 ng) was used for cDNA synthesis using a multi-cDNA kit and random oligonucleotide CCATCCAATCG-GTAGTAGCG; or off the shelfprimers from ABI. All primers were purchased from ABI.
All probes were labeled with 5′-6-carboxyfluoroscein and 3′-6-carboxytetramethylrhodamin. The Hes1 amplicon was detected with SYBR green.
Samples were run on an ABI 7700 sequence detection system or a Lightcycler (Roche Diagnostics Ltd., Lewes, United Kingdom). Relative quantification of mRNA levels was performed using the comparative cycle threshold (C T ) method, following the manufacturer's instructions (ABI).
Notch-signaling reporter assay. CHO cells were stably transfected with a full-length cDNA encoding human Notch2, which was isolated from a commercially available cDNA bank (OriGen Technologies Inc., Rockville, Maryland, USA). These cells were further transfected with a construct containing a multimerized (10 times) CBF1 response element upstream of a luciferase cDNA. Stable transfectants (CHO/N2-luc, 2 × 10 4 cells/well) were placed into white 96-well OptiPlates (Canberra Packard Ltd., Pangbourne, United Kingdom) and allowed to adhere for 1 hour at 37°C before adding the L cell transfectants or control untransfected CHO cells at 2 × 10 5 /well in medium containing 10 mM LiCl. L cells and control untransfected CHO cells were mitomycin C treated (100 µg/ml, 70 minutes, 37°C) before they were added to the assay. Cultures were incubated at 37°C for 24 hours. Supernatants were removed from wells, and cells were washed and lysed by the addition of 100 µl of Glo lysis buffer (Promega UK Ltd., Southampton, United Kingdom). After 5 minutes at room temperature, 100 µl of SteadyGlo luciferase assay reagent (Promega UK Ltd.) was added, and the luminescence was read in a TopCount (Canberra Packard Ltd.).
Mice. . The mice were used in both PLN assays and heart transplantation experiments. C57BL/10 mice were used as allogeneic donors, BALB/c mice were used as thirdparty donors, and C3H/HeJ mice were used as recipients.
Heterotopic heart transplantation. Heterotopic heart transplants were performed as described by Corry (22) . Animals were injected with cells 14 days before transplantation, as indicated. Doses of cells were based on those used previously (20) . Injections were as follows: Bone marrow-derived DCs. Bone marrow cells were harvested, red cells lysed, and the remaining cells were cultured at a concentration of 2 × 10 6 cells/ml in RPMI-1640 plus 10% FCS plus antibiotics (GibcoBRL; Life Technologies Ltd.) with GM-CSF and IL-4 (10 ng/ml each; PeproTech EC Ltd., Northampton, United Kingdom). Two milliliters of the medium was replaced on days 2 and 4. DCs were used on day 7.
Indirect allopresentation. Seven day-cultured DCs were treated with mitomycin C (Sigma-Aldrich Co. Ltd.) at 50 µg/ml for 1 hour at 37°C. Cells were washed three times and incubated overnight in serum-free RPMI-1640 to induce apoptosis. These were fed to growing DCs on days 3 to 5 of their culture. On day 7, DCs that had been fed with apoptotic DCs were used in PLN assays.
Dl1-Fc cultures. Ninety-six-or 24-well plates were coated with anti-hamster IgG1 and anti-human IgG4 capture Ab's at 1 µg/ml in PBS. Plates were incubated overnight at 4°C and washed three times with PBS before addition of hamster anti-mouse CD3 (clone 145.2C11, concentrations as shown) and Dl1-Fc (various concentrations as shown). Dl1-Fc protein was purified from stably transfected CHO cell supernatants and was shown to be active in a Notch-signaling assay (23) . Plates were then incubated for 2 hours at 37°C and washed three times with PBS. CD4 + or CD8 + cells were positively selected from red cell lysed spleen cell suspensions using Miltenyti microbeads according to the manufacturer's instructions. For cytokine analysis in 96-well plates, 2 × 10 5 to 3 × 10 5 cells/well were added to treated plates with soluble anti-CD28 at 2 µg/ml. For RT-PCR in 24-well plates, 2.5 × 10 6 cells/well were added. Coating and activating Ab's were from PharMingen. Cells were incubated for 5 days before removal of supernatants for cytokine analysis by ELISA using Ab pairs from R&D Systems Europe Ltd. (Oxon, United Kingdom) or for 4 hours before collection for RNA preparation.
Statistical analysis. Statistics were performed using MannWhitney test (PLN assay) or Wilcoxon's log-rank test (transplants) with Bonferroni correction as appropriate. In our experiments, however, the Dl1-transfected cells signaled well and did not have upregulated expression of alternative ligands. Taken together, these findings indicate that the effects observed in functional assays were due solely to the expression of Dl1 introduced into these cells by transfection.
Results
Characterization of L cells. L cells express endogenous
We also wished to know whether Notch signaling could be directly activated in T cells. To explore this, T cells stimulated in the presence or absence of Notch ligand were assessed for increased transcript levels of Hes1. Hes1 is a downstream target of Notch signaling, and an increase in transcripts of this gene indicates active Notch signaling in cells, including those of the hematopoietic system (2, 24, 25) . Preliminary experiments using L cell stimulators indicated that, indeed, the Dl1 transfectants, but not their parental counterparts, could deliver a signal through Notch as assessed by increased expression of Hes1 (data not shown). We were concerned, however, that because the Dl1 transfectants expressed high levels of Hes1 (data not shown), small contamination with these cells could bias our results. We therefore used a Dl1-Fc fusion protein to stimulate Notch signaling in T cells stimulated with CD3 and CD28 Ab's. These experiments showed that Dl1-mediated ligation of Notch is able to induce upregulated transcript levels of Hes1 in both CD4 + and CD8 + cells, thereby indicating that Notch signaling can be directly activated in T cells (Figure 2c) .
Dl1-transfected L cells are not immunogenic and can induce antigen-specific unresponsiveness. The immunogenicity and ability to regulate immune responses of the L cells was first assessed using a system of local antigen challenge, the PLN assay. In this assay animals are challenged in the footpad with antigen, and responses are measured in the draining PLN. In PLN assays, neither A b /Dl1 nor K b /Dl1 were immunogenic. Moreover, these Notch ligand transfectants were capable respectively of inducing unresponsiveness to a subsequent challenge with A b (Figure 3a Unresponsiveness is not induced to MHC antigens presented through the indirect pathway. Transplantation antigens can be presented either directly, that is on cells expressing the alloantigen, or indirectly, that is as processed peptides on self APCs. Both pathways have been shown to be important in evoking acute graft rejection (26) (27) (28) . The experiments described above indicated that T cells recognizing alloantigen directly on the expressing cell were inhibited by the pretreatment protocol, and this was confirmed in PLN assays where the APCs used in challenge were DCs rather than LNCs (direct; Figure 3d . Under these culture conditions, however, the secretion of other cytokines was very low. Use of the Dl1-Fc fusion protein described above allowed us to further explore the effects of Notch ligation on isolated populations of cells in culture under conditions where many different cytokines could be produced. Indeed, we have shown recently that Notch ligation in CD4 + cells by Dl1-Fc induces a selective enhancement of IL-10 production following TCR-mediated activation (23) . As demonstrated (Figure 6b ) using splenic CD8 + cells, ligation of Notch in the presence of T cell receptor and costimulatory signals also has profound effects on the type of cytokine produced, dramatically decreasing the level of IFN-γ while increasing over threefold the amount of IL-10 produced. Levels of IL-2 were also decreased and those of IL-13 were unaffected, suggesting that Notch signaling inhibits differentiation down a T1 pathway in these experiments.
Discussion
We have shown, we believe for the first time, that pretreatment with cells expressing a ligand of the Deltalike family together with alloantigen is able to inhibit the response to subsequent exposure to the same antigen in an antigen-specific fashion. In the context of organ transplantation this resulted in the prolongation of graft survival under conditions in which pretreatment with alloantigen alone had no beneficial effect. Mechanistically, this inhibition was shown to be dependent upon the presence of CD8 + cells and did not associate with increased apoptosis in responding cells. Although engraftment was not permanent, we provided evidence that this was due to the fact that our pretreatment regimen did not target the indirect pathway of presentation. Cell culture experiments indicated that ligation of Notch on CD8 + responder cells was able to alter their cytokine expression potential, diverting them away from a T1-type response while enhancing their ability to express IL-10.
Whether the different mammalian ligand families, Jagged and Delta-like, signal for the same outcome in mature lymphocytes is not known. There is evidence from the developing hematopoietic system that these ligands do not have completely redundant activities, with Dl1 being able to completely inhibit B cell differentiation whereas Jagged1 has no effect. Furthermore, there is evidence that their signaling potential is modulated differentially by proteins such as fringe (2, 30) . Previously, we performed experiments in which DCs expressing human Jagged1 and pulsed with peptide were able to inhibit responses to the soluble protein Der p 1 (17) and showed that the inhibition was mediated by a CD4 + population of cells. In those studies CD8 + cells capable of inhibiting responses in adoptive transfer experiments were not generated, but this may well be a function of the antigen used, rather than an inherent difference in the ability of the two different Notch ligands used to affect different populations of cells. Experiments are in progress to further compare the effects of signaling through the two families of ligands on the peripheral immune system.
The lack of an effect of the Dl1-expressing L cells on T cell responses to indirectly presented antigen could be due to the fact that Notch ligand on APCs is cis-and not trans-acting, or it may be that in the PLN, T cells with specificity for indirectly presented alloantigen would not come sufficiently close to the Dl1-transfected L cells to be affected by the presence of Notch ligand. Alternatively, it could be that inherent differences in the requirements for stimulation by direct and indirect pathways as suggested by others (31) affects the unresponsiveness induced by Notch ligation. These issues, and in particular whether Notch ligand on APCs is either cis-or trans-acting in this system are currently under investigation.
Despite the significant prolongation observed in transplants of all animals pretreated with K b /Dl1 plus A b /Dl1 cells, all animals eventually rejected their grafts. This was perhaps not surprising in view of the fact that our pretreatment regimen targeted only the direct pathway of antigen presentation, and it is clear from the work of others that indirect presentation can result in rapid graft rejection (26) (27) (28) . We presented evidence that an inhibitory CD8 + cell is responsible for the prolonged graft survival observed since depletion of this population at the time of grafting, a strategy used previously by others to demonstrate a similar phenomenon (32), completely abrogated the beneficial effects of the pretreatment protocol. There are many reports of CD8 + suppressor/inhibitory cells that operate through a variety of cell contact-dependent and independent mechanisms (33) (34) (35) (36) (37) (38) (39) . In the work of others, CD8 + regulatory cells have been documented recently both in patients with antigen-specific unresponsiveness to influenza matrix peptide (40) and after culture of human T cells with CD40 ligand-activated plasmacytoid DCs (41) . In the latter study the regulatory cells were shown to produce elevated levels of IL-10, but reduced levels of all other cytokines tested compared with CD8 + effector cells activated by monocyte-derived DCs. Our data provide further evidence implicating the activity of CD8 + cells in antigen-specific unresponsiveness in vivo, although our data do not define the cell lineage involved.
Our data do not exclude the possibility that a CD4 + cell is also involved in the beneficial effects of Notch ligand-transfected cells. Indeed, the requirement for the inclusion of MHC class II-expressing transfectants in the pretreatment protocol, taken together with our previous data (17) , argues strongly in favor of the involvement of CD4 + , MHC class II-reactive cells in collaboration with the CD8 + cells. There are many reports of CD4 + regulatory cells with a variety of phenotypic and functional characteristics (42) (43) (44) (45) (46) (47) (48) , and it will be of interest to examine whether any of these cells are induced or expanded in the present system. Such cells, which include the naturally occurring CD4 + CD25 + regulatory cells (44, 45) and those induced or expanded by experimental manipulation (42, (48) (49) (50) (51) (52) , have been reported variably to depend upon cytokines, including IL-10, for their induction and/or function. The relationship between naturally occurring regulatory cells and those induced or expanded by experimental manipulation is poorly defined, but it is apparent for at least one cell type (i.e., IL-10-producing Tr1 cells) that they have different origins (53) . The eventual loss of grafts in our experiments could be explained by the loss of the CD8 + (and putative CD4 + ) inhibitory populations since the activating signal for them (i.e., APCs of graft origin) is lost rapidly from the graft (54), and it is clear in other models of transplantation that inhibition or tolerance can be maintained only in the continued presence of antigen (55) .
Epitope spreading, in which tolerance induced to one peptide of an antigen extends to the entire protein, is a common feature of many experimental models of tolerance. Similarly, in other experimental transplantation models, long-term engraftment or tolerance may be achieved with preoperative treatment regimens that include only single-donor alloantigens, suggesting that in these experiments spreading of tolerance can not only account for unresponsiveness to haplotypes recognized directly, but also to alloantigen recognized indirectly (56) . Indeed, it is becoming clear that in longterm surviving recipients of allogeneic grafts, it is the CD4 + T cells that recognize antigen indirectly that maintain the tolerant state (57, 58) . These and other transplantation tolerance studies have in common a phase of nonspecific immunosuppression during the induction of unresponsiveness that will target all T cells whether they recognize alloantigen directly or indirectly. This is not the case in our experiments, and it is likely that nonspecific immunosuppression will result in the ablation and/or inactivation of T cells recognizing alloantigen directly and indirectly, allowing the emergence of a dominant population of regulatory cells. Since in long-term surviving grafts the primary stimulus will be to regulatory T cells recognizing alloantigen indirectly, it is not surprising that this population is maintained in such experiments. It has been difficult to raise inhibitory cells that regulate responses to directly presented alloantigen (31), but our data establish that this may indeed be possible.
Our understanding, as derived from developmental systems, indicates that the Notch-signaling pathway controls cell fate choices through influencing proliferation, differentiation, and death (1) . While Notch may itself direct cell fate, more usually it acts by inhibiting differentiation along one pathway, thereby allowing the cell to be influenced by other cell extrinsic or intrinsic cues to differentiate down an alternate pathway. The data presented in this paper is consistent with the hypothesis that Notch signaling in mature CD8 + lymphocytes inhibits differentiation along a T1 program, thereby allowing them to mature into a T2/inhibitory population. The integration of Notch signaling with T cell receptor and costimulatory and cytokine-mediated signaling is obviously critical to the outcome of this process and the subject of further investigation in our laboratories.
We have demonstrated that delivery of cells coexpressing antigen and a Notch ligand of the Delta-like family can subvert, in an antigen-specific fashion, the normally powerful immune response to alloantigen, even when that antigen is delivered by a route that would otherwise be sensitizing. This inhibition is dependent on the presence of CD8 + cells at the time of antigen challenge. We have shown that animals pretreated with Dl1-expressing cells showed a very early inhibition of cell accumulation at the site of antigen challenge and that direct ligation of the Notch receptor on splenic CD8 + cells enhances the production of IL-10 while dramatically reducing the production of IFN-γ. These latter data suggest that Notch signaling can inhibit differentiation of mature CD8 + cells down a T1 pathway.
The ability to induce antigen-specific unresponsiveness without concomitant nonspecific immunosuppression is highly desirable and should not only be beneficial in the context of bone marrow and organ transplantation, but also in the context of diseases of autoimmune or allergic pathology.
